Vitiligo
Also known as: Leukoderma
Vitiligo is a chronic skin condition in which the cells that produce melanin (melanocytes) are destroyed, leading to irregular white patches on the skin. It can affect any area of the body and occurs in all skin types, though it is more noticeable in darker skin tones. While vitiligo is not medically dangerous, it can have significant psychological and emotional effects.
Last updated November 10, 2026
Understanding Vitiligo
Vitiligo is an acquired loss of skin pigment that shows up as sharply bordered, milk-white patches, most often on the face, hands, elbows, knees, genitals and around body openings. It affects roughly 0.5 to 2 percent of people worldwide, about one in a hundred in the United States, equally in men and women and in every skin tone, although the contrast is far more visible on darker skin. Half of all cases begin before age 20 and three quarters before 30. About 90 percent are non-segmental, meaning patches appear on both sides of the body and tend to come and go over years; the segmental form stays on one side, usually stops spreading within a year or two, and responds better to surgery. Vitiligo is not infectious and not dangerous in itself, but it travels with other autoimmune conditions: around 15 percent of people with vitiligo have autoimmune thyroid disease, which is why a TSH and thyroid antibodies belong in the first workup.
The white patches are places where melanocytes, the pigment cells at the base of the epidermis, have been removed. In non-segmental vitiligo the removal is done by the immune system: cytotoxic T cells that recognize melanocyte proteins are drawn into the skin by the signaling molecules interferon-gamma and CXCL10, and the same JAK-STAT pathway that carries that signal is what the newest drugs block. Melanocytes in vitiligo also handle oxidative stress poorly, which is why physical injury, sunburn or friction can seed a new patch along the line of damage, a pattern called the Koebner phenomenon. The disease is unpredictable: it can smolder for years, flare after illness or stress, and about a third of people see some patches partially repigment on their own, usually on sun-exposed skin. Repigmentation comes from melanocyte stem cells in hair follicles, which is why hairy areas such as the face recover and hairless areas such as fingertips, knuckles and ankles rarely do, and why a patch whose hairs have turned white is unlikely to refill.
Treatment aims to stop active spread and then coax pigment back, and both take months. For limited patches, the British Association of Dermatologists 2022 guideline recommends a potent topical corticosteroid, or a calcineurin inhibitor (tacrolimus, pimecrolimus) on the face, applied for at least 3 to 6 months. Narrowband UVB two to three times a week for 6 to 12 months is the backbone for widespread disease: in a 2017 meta-analysis of 35 studies and 1,428 patients, at least 75 percent repigmentation was reached by 19 percent of patients at 6 months and 36 percent at 12 months. The first new drug class in decades is ruxolitinib 1.5 percent cream, a topical JAK inhibitor approved in 2022 for non-segmental vitiligo from age 12: in the twin TRuE-V trials (674 patients), about 30 percent of people reached 75 percent facial repigmentation at 24 weeks versus 7 to 11 percent on vehicle, rising to about half by week 52. Grafting works for stable segmental patches, and depigmentation is an option when more than half the skin is affected.
No supplement repigments vitiligo on its own, and it is worth saying that plainly before describing the few with any trial data. The most studied is Ginkgo biloba, which in a 52-person placebo-controlled trial stopped active spread in most participants and produced marked repigmentation in a minority; the trial was small and has not been repeated at scale. An antioxidant combination of alpha-lipoic acid, vitamins C and E and polyunsaturated fatty acids roughly doubled the proportion of patients reaching 75 percent repigmentation when added to narrowband UVB in a 35-person study. Vitamin D levels are low in many people with vitiligo and are worth checking and correcting, but the only treatment report used a dangerous 35,000 IU daily dose with no control group, so it tells us little. Zinc sulfate added to a topical steroid made no difference in a randomized trial, oral or topical turmeric has only cell-culture data, and homeopathy, gluten-free diets and copper bracelets have none. The honest role of these products is as low-cost adjuncts to phototherapy or a JAK cream, never as the plan.
The most common mistake is giving up too early. Phototherapy and topical treatments usually show nothing for the first 8 to 12 weeks, and the first sign of response is pinpoint dots of color around hair follicles, not a shrinking border; people who stop at month two never find out whether month six would have worked. The second mistake is trying to tan the surrounding skin to reduce contrast, or deliberately burning the white patches to stimulate them. Depigmented skin has no melanin to absorb UV, burns fast, and a burn can trigger new patches through the Koebner effect. Use a broad-spectrum SPF 30 or higher on exposed patches, and leave controlled UV exposure to a phototherapy unit where the dose is measured. Finally, do not let the physical harmlessness of vitiligo hide its weight: depression and social anxiety are common, and camouflage cosmetics, self-tanners containing dihydroxyacetone, and support groups are legitimate parts of care.
At a Glance
- Common symptoms
- Patchy loss of skin color, typically on the face, hands, arms, and feet, Premature graying or whitening of hair, eyelashes, eyebrows, or beard, Loss of color in the tissues inside the mouth and nose
- Main treatments
- Topical corticosteroids to help restore color in early patches, Topical calcineurin inhibitors such as tacrolimus for facial vitiligo, Narrowband UVB phototherapy
- Category
- Dermatological · Affects approximately 0.5-2% of the global population
- See a doctor if
- New white patches appearing on the skin
Symptoms
Causes
- Autoimmune destruction of melanocytes
- Genetic predisposition with multiple genes involved
- Possible environmental triggers such as sunburn or chemical exposure
- Oxidative stress damaging melanocytes
Risk Factors
- Family history of vitiligo or other autoimmune conditions
- Personal history of autoimmune diseases such as thyroid disease or alopecia areata
- Onset typically before age 30
Diagnosis
- Physical examination of skin under natural and Wood's lamp light
- Skin biopsy to confirm absence of melanocytes
- Blood tests to check for associated autoimmune conditions such as thyroid disease
- Eye examination to rule out uveitis
Treatment
- Topical corticosteroids to help restore color in early patches
- Topical calcineurin inhibitors such as tacrolimus for facial vitiligo
- Narrowband UVB phototherapy
- Combination of psoralen and UVA therapy (PUVA)
- Surgical options including skin grafting for stable vitiligo
- Depigmentation therapy for extensive vitiligo covering more than 50% of the body
Natural remedies for vitiligo: what the evidence says
Ranked by the strength of human evidence for vitiligo specifically. These sit alongside medical care, not in place of it.
Ginkgo Biloba
Preliminary evidenceIn a double-blind trial of 52 people with slowly spreading, limited vitiligo, 40 mg of standardized ginkgo extract three times daily for 12 weeks halted progression in 20 of 25 on ginkgo versus 8 of 22 on placebo, and 10 versus 2 showed marked repigmentation. A later 12-week open pilot of 60 mg twice daily in 12 people found progression stopped and an average 15 percent repigmentation on the VASI score. Both studies were small, short and from single centers, so the evidence stays preliminary.
- Studied dose
- 40 mg standardized extract (24 percent flavone glycosides) three times daily, or 60 mg twice daily, for at least 12 weeks.
- Cautions
- Increases bleeding risk with warfarin, aspirin, clopidogrel and NSAIDs; stop 2 weeks before surgery. Can lower the seizure threshold and may interact with omeprazole and some antidepressants. Avoid in pregnancy.
Alpha-Lipoic Acid
Preliminary evidenceIn a 35-patient trial, an antioxidant combination of 50 mg alpha-lipoic acid, 100 mg vitamin C, 40 mg vitamin E and polyunsaturated fatty acids was started 8 weeks before and continued through 6 months of twice-weekly narrowband UVB. 47 percent of the supplemented group achieved more than 75 percent repigmentation compared with 18 percent on phototherapy alone, and blood markers of oxidative stress fell. The combination was tested only alongside phototherapy, not instead of it.
- Studied dose
- 50 mg alpha-lipoic acid daily as part of an antioxidant combination, taken with phototherapy; higher stand-alone doses have not been studied in vitiligo.
- Cautions
- Can lower blood sugar and add to the effect of diabetes medication. Separate from thyroid medication by several hours and tell your dermatologist, since it may change the UVB dose you need.
Vitamin D
Preliminary evidencePooled observational studies find 25-hydroxyvitamin D levels are lower in people with vitiligo than in controls, and vitamin D helps melanocytes survive oxidative stress in the laboratory. The only treatment report gave 16 patients 35,000 IU daily for 6 months on a calcium-restricted diet; 14 showed 25 to 75 percent repigmentation, but there was no control group and the dose risks dangerously high blood calcium. Topical calcipotriol adds little to steroids in randomized trials. Check a vitamin D level and correct a deficiency, but do not expect pigment from it.
- Studied dose
- 1,000 to 2,000 IU vitamin D3 daily to keep 25-hydroxyvitamin D above 30 ng/mL; megadoses are not recommended.
- Cautions
- Doses above 4,000 IU daily without monitoring can cause high calcium, kidney stones and kidney injury. Use caution with thiazide diuretics and in sarcoidosis or hyperparathyroidism.
Vitamin B12
Preliminary evidenceVitamin B12 and folate deficiency are more common in vitiligo, partly through the link with autoimmune gastritis and pernicious anemia. In an uncontrolled Swedish series of 100 patients given 1 mg vitamin B12 and 5 mg folic acid twice daily with regular sun exposure, repigmentation occurred in 52 and spread stopped in 64 percent, but without a placebo group it is impossible to separate the vitamins from the sunlight. No randomized trial has followed.
- Studied dose
- 1,000 mcg vitamin B12 daily with 400 to 800 mcg folate; check a serum B12 first.
- Cautions
- Very safe at these doses. High-dose folic acid can mask a B12 deficiency on blood tests, so measure B12 before starting folate alone.
Vitamin E
Preliminary evidenceVitamin E was part of the antioxidant combination that improved narrowband UVB response in the 35-patient Italian trial, and a 24-patient study found oral vitamin E taken alongside phototherapy raised blood antioxidant markers and gave a modestly higher repigmentation rate. No trial has tested vitamin E alone against placebo in vitiligo.
- Studied dose
- 40 to 400 IU mixed tocopherols daily, taken with phototherapy.
- Cautions
- Doses above 400 IU add to bleeding risk with anticoagulants and antiplatelet drugs and have been linked to a small rise in mortality in long-term trials, so stay at the low end.
What matters day to day
- Apply broad-spectrum SPF 30 or higher to exposed patches every morning and reapply outdoors: depigmented skin has no melanin and burns within minutes, and a sunburn can trigger new patches through the Koebner effect.
- Protect skin from friction and minor injury, with gloves for rough work and padding on belts, straps and watch bands: about a third of people with vitiligo develop new patches along lines of trauma, and the hands and wrists are the usual sites.
- Ask for a TSH and thyroid peroxidase antibody test at diagnosis and every 1 to 2 years: around 15 percent of people with vitiligo have autoimmune thyroid disease, often before it causes symptoms.
- Avoid hair dyes, rubber and adhesives containing phenolic compounds such as para-tertiary-butylphenol and monobenzone unless patch-tested: these chemicals can kill melanocytes and cause occupational or contact vitiligo.
- Keep a dated photo record of your patches every 3 months under the same light: it is the only reliable way to tell whether disease is active or stable, which decides between a steroid mini-pulse and a surgical graft.
- Treat mood as part of the condition: screening studies find depression or anxiety in roughly a quarter of adults with vitiligo, and cosmetic camouflage and peer support measurably improve quality of life.
Prevention
- No known prevention due to autoimmune and genetic basis
- Sun protection to prevent sunburn on depigmented skin
- Managing stress which may trigger or worsen the condition
When to See a Doctor
- New white patches appearing on the skin
- Existing patches that are spreading or increasing in size
- Emotional distress related to skin appearance changes
- For evaluation of associated autoimmune conditions
Frequently Asked Questions
References
- Rosmarin D, Passeron T, Pandya AG, et al.. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo (TRuE-V1 and TRuE-V2). New England Journal of Medicine (2022)
- Bae JM, Jung HM, Hong BY, et al.. Phototherapy for vitiligo: a systematic review and meta-analysis. JAMA Dermatology (2017)
- Eleftheriadou V, Atkar R, Batchelor J, et al.. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. British Journal of Dermatology (2022)
- Parsad D, Pandhi R, Juneja A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clinical and Experimental Dermatology (2003)
- Dell'Anna ML, Mastrofrancesco A, Sala R, et al.. Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. Clinical and Experimental Dermatology (2007)
- Vrijman C, Kroon MW, Limpens J, et al.. The prevalence of thyroid disease in patients with vitiligo: a systematic review. British Journal of Dermatology (2012)
- Yaghoobi R, Omidian M, Bagherani N. Original article: the effects of oral zinc sulfate with topical corticosteroid in vitiligo. Journal of Research in Medical Sciences (2011)
- Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. The Lancet (2015)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. Vitiligo (2022)View source
- MedlinePlus, National Library of Medicine. Vitiligo (2024)View source
Related Conditions
Lab tests that relate to vitiligo
Have questions about Vitiligo?
Ask Mother Nature AI for personalized, evidence-based guidance.
Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.